Target intelligence / Profile preview

Potassium channel protein subunit Kir6.2 (Kir6.2)

Target
Kir6.2
Molecular classification
Ion channel, Inwardly rectifying potassium (Kir) channel, ATP-sensitive potassium (KATP) channel component
01

Overview

Potassium channel protein subunit Kir6.2 is a pore-forming component of ATP-sensitive potassium (KATP) channels, primarily encoded by the gene KCNJ11. These channels are hetero-octameric complexes composed of four central Kir6.2 subunits surrounded by four regulatory sulfonylurea receptor 1 (SUR1) units; together they play a crucial role in linking cellular metabolism with electrical excitability across various tissues, most notably pancreatic β-cells where they regulate insulin secretion in response to blood glucose levels. Mutations in Kir6.2 can lead either to congenital hyperinsulinism or permanent neonatal diabetes mellitus depending on whether they increase or decrease sensitivity to ATP inhibition respectively; some mutations are also associated with neurological symptoms when affecting neuronal isoforms. Drugs such as glibenclamide act as pharmacochaperones or inhibitors by binding within SUR1 but stabilizing interactions critical for proper assembly and function involving both SUR and Kir components—ultimately modulating ion flow through this essential metabolic sensor complex.

Other names
ATP-sensitive inward rectifier potassium channel 11KCNJ11 (gene name)Inward rectifier potassium channel Kir6.2KATP channel subunit Kir6.2
02

Mechanism of action

Channel inhibition by sulfonylureas and related drugs, which bind the regulatory SUR subunit but affect the function of the Kir6.2 pore-forming unit, leading to closure of the KATP channels and stimulation of insulin secretion from pancreatic β-cells.

03

Biological functions

Regulation of membrane potentialCoupling of cell metabolism to electrical activityControl of insulin secretion in pancreatic β-cellsResponse to metabolic and ischemic conditions
04

Disease associations

Diabetes mellitus, especially permanent neonatal diabetes mellitus (PNDM)Congenital hyperinsulinism
05

Safety considerations

Risk of hypoglycemia with drugs that inhibit KATP channels due to excessive insulin release in non-diabetic patients or overdose situations.
06

Interacting drugs

Glibenclamide

2 more in the full profile.

Beyond the preview

Go deeper on Potassium channel protein subunit Kir6.2 (Kir6.2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium channel protein subunit Kir6.2 (Kir6.2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call